Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity
BackgroundDipeptidyl peptidase 4 (DPP-4, also known as CD26) binds with adenosine deaminase (ADA) to activate T lymphocytes. Here, we investigated whether ADA activity is specifically affected by treatment with DPP-4 inhibitor (DPP4I) compared with other anti-diabetic agents.MethodsFasting ADA activ...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Diabetes Association
2011-04-01
|
| Series: | Diabetes & Metabolism Journal |
| Subjects: | |
| Online Access: | http://e-dmj.org/Synapse/Data/PDFData/2004DMJ/dmj-35-149.pdf |
| _version_ | 1828860834443427840 |
|---|---|
| author | Jae-Geun Lee Dong Gu Kang Jung Re Yu Youngree Kim Jinsoek Kim Gwanpyo Koh Daeho Lee |
| author_facet | Jae-Geun Lee Dong Gu Kang Jung Re Yu Youngree Kim Jinsoek Kim Gwanpyo Koh Daeho Lee |
| author_sort | Jae-Geun Lee |
| collection | DOAJ |
| description | BackgroundDipeptidyl peptidase 4 (DPP-4, also known as CD26) binds with adenosine deaminase (ADA) to activate T lymphocytes. Here, we investigated whether ADA activity is specifically affected by treatment with DPP-4 inhibitor (DPP4I) compared with other anti-diabetic agents.MethodsFasting ADA activity, in addition to various metabolic and biochemical parameters, were measured in 262 type 2 diabetes mellitus (T2DM) patients taking various anti-diabetic agents and in 46 non-diabetic control subjects.ResultsADA activity was increased in T2DM patients compared with that in non-diabetic control subjects (mean±standard error, 23.1±0.6 U/L vs. 18.6±0.8 U/L; P<0.05). ADA activity was correlated with fasting plasma glucose (r=0.258, P<0.05), HbA1c (r=0.208, P<0.05), aspartate aminotransferase (r=0.325, P<0.05), and alanine aminotransferase (r=0.248, P<0.05). Compared with the well-controlled T2DM patients (HbA1c<7%), the poorly controlled group (HbA1c>9%) showed significantly increased ADA activity (21.1±0.8 U/L vs. 25.4±1.6 U/L; P<0.05). The effect of DPP4I on ADA activity in T2DM patients did not differ from those of other oral anti-diabetic agents or insulin. T2DM patients on metformin monotherapy showed a lower ADA activity (20.9±1.0 U/L vs. 28.1±2.8 U/L; P<0.05) compared with that of those on sulfonylurea monotherapy.ConclusionOur results show that ADA activity is increased in T2DM patients compared to that in non-diabetic patients, is positively correlated with blood glucose level, and that DPP4I has no additional specific effect on ADA activity, except for a glycemic control- or HbA1c-dependent effect. |
| first_indexed | 2024-12-13T02:48:13Z |
| format | Article |
| id | doaj.art-ac75bffd9d504b3191c3af3c4b7a3c38 |
| institution | Directory Open Access Journal |
| issn | 2233-6079 2233-6087 |
| language | English |
| last_indexed | 2024-12-13T02:48:13Z |
| publishDate | 2011-04-01 |
| publisher | Korean Diabetes Association |
| record_format | Article |
| series | Diabetes & Metabolism Journal |
| spelling | doaj.art-ac75bffd9d504b3191c3af3c4b7a3c382022-12-22T00:02:08ZengKorean Diabetes AssociationDiabetes & Metabolism Journal2233-60792233-60872011-04-0135214915810.4093/dmj.2011.35.2.1492738Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA ActivityJae-Geun LeeDong Gu KangJung Re YuYoungree KimJinsoek KimGwanpyo KohDaeho LeeBackgroundDipeptidyl peptidase 4 (DPP-4, also known as CD26) binds with adenosine deaminase (ADA) to activate T lymphocytes. Here, we investigated whether ADA activity is specifically affected by treatment with DPP-4 inhibitor (DPP4I) compared with other anti-diabetic agents.MethodsFasting ADA activity, in addition to various metabolic and biochemical parameters, were measured in 262 type 2 diabetes mellitus (T2DM) patients taking various anti-diabetic agents and in 46 non-diabetic control subjects.ResultsADA activity was increased in T2DM patients compared with that in non-diabetic control subjects (mean±standard error, 23.1±0.6 U/L vs. 18.6±0.8 U/L; P<0.05). ADA activity was correlated with fasting plasma glucose (r=0.258, P<0.05), HbA1c (r=0.208, P<0.05), aspartate aminotransferase (r=0.325, P<0.05), and alanine aminotransferase (r=0.248, P<0.05). Compared with the well-controlled T2DM patients (HbA1c<7%), the poorly controlled group (HbA1c>9%) showed significantly increased ADA activity (21.1±0.8 U/L vs. 25.4±1.6 U/L; P<0.05). The effect of DPP4I on ADA activity in T2DM patients did not differ from those of other oral anti-diabetic agents or insulin. T2DM patients on metformin monotherapy showed a lower ADA activity (20.9±1.0 U/L vs. 28.1±2.8 U/L; P<0.05) compared with that of those on sulfonylurea monotherapy.ConclusionOur results show that ADA activity is increased in T2DM patients compared to that in non-diabetic patients, is positively correlated with blood glucose level, and that DPP4I has no additional specific effect on ADA activity, except for a glycemic control- or HbA1c-dependent effect.http://e-dmj.org/Synapse/Data/PDFData/2004DMJ/dmj-35-149.pdfAdenosine deaminaseDiabetes mellitus, type 2Dipeptidyl peptidase |
| spellingShingle | Jae-Geun Lee Dong Gu Kang Jung Re Yu Youngree Kim Jinsoek Kim Gwanpyo Koh Daeho Lee Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity Diabetes & Metabolism Journal Adenosine deaminase Diabetes mellitus, type 2 Dipeptidyl peptidase |
| title | Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity |
| title_full | Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity |
| title_fullStr | Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity |
| title_full_unstemmed | Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity |
| title_short | Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity |
| title_sort | changes in adenosine deaminase activity in patients with type 2 diabetes mellitus and effect of dpp 4 inhibitor treatment on ada activity |
| topic | Adenosine deaminase Diabetes mellitus, type 2 Dipeptidyl peptidase |
| url | http://e-dmj.org/Synapse/Data/PDFData/2004DMJ/dmj-35-149.pdf |
| work_keys_str_mv | AT jaegeunlee changesinadenosinedeaminaseactivityinpatientswithtype2diabetesmellitusandeffectofdpp4inhibitortreatmentonadaactivity AT donggukang changesinadenosinedeaminaseactivityinpatientswithtype2diabetesmellitusandeffectofdpp4inhibitortreatmentonadaactivity AT jungreyu changesinadenosinedeaminaseactivityinpatientswithtype2diabetesmellitusandeffectofdpp4inhibitortreatmentonadaactivity AT youngreekim changesinadenosinedeaminaseactivityinpatientswithtype2diabetesmellitusandeffectofdpp4inhibitortreatmentonadaactivity AT jinsoekkim changesinadenosinedeaminaseactivityinpatientswithtype2diabetesmellitusandeffectofdpp4inhibitortreatmentonadaactivity AT gwanpyokoh changesinadenosinedeaminaseactivityinpatientswithtype2diabetesmellitusandeffectofdpp4inhibitortreatmentonadaactivity AT daeholee changesinadenosinedeaminaseactivityinpatientswithtype2diabetesmellitusandeffectofdpp4inhibitortreatmentonadaactivity |